Abstract
In recent years, there has been an expansion of the understanding of how epigenetic dysregulation plays a role in tumorigenesis, progression, metastasis and treatment resistance. Evidence has focused on two common and well-studied “epigenetic codes”, i.e., DNA methylation and histone posttranslational modification, which regulate the transcriptional status in various types of cancer and the corresponding target agents.
Aside from “writers” and “erasers”, which refer to enzymes that catalyze and remove posttranslational modifications, respectively, “readers” bind to target proteins and recruit “writers” and “erasers” for regulating gene expression. A number of selective and potent anticancer compounds have been reported, some of which are in preclinical or clinical trials that have shown promising results, primarily against malignant neoplasms such as hematologic malignancies, with the subsequent emerging development of both monotherapy and co-administration with traditional cytotoxic medicines against solid tumors. Second-generation epigenetic agents such as EZH2 and BET inhibitors have greatly progressed. Epigenetic dysregulation has also provided feasibility for the diagnosis and treatment of cancer. In this review, we summarize the progress in epigenetics and drug discovery for cancer and certain clinical trials that may provide a perspective for future development.
Keywords: Epigenetic, anticancer drug discovery, DNA methylation, histone posttranslational modification.
Anti-Cancer Agents in Medicinal Chemistry
Title:Current Status of Epigenetics and Anticancer Drug Discovery
Volume: 16 Issue: 6
Author(s): Ping Jin and Xiaofei Chen
Affiliation:
Keywords: Epigenetic, anticancer drug discovery, DNA methylation, histone posttranslational modification.
Abstract: In recent years, there has been an expansion of the understanding of how epigenetic dysregulation plays a role in tumorigenesis, progression, metastasis and treatment resistance. Evidence has focused on two common and well-studied “epigenetic codes”, i.e., DNA methylation and histone posttranslational modification, which regulate the transcriptional status in various types of cancer and the corresponding target agents.
Aside from “writers” and “erasers”, which refer to enzymes that catalyze and remove posttranslational modifications, respectively, “readers” bind to target proteins and recruit “writers” and “erasers” for regulating gene expression. A number of selective and potent anticancer compounds have been reported, some of which are in preclinical or clinical trials that have shown promising results, primarily against malignant neoplasms such as hematologic malignancies, with the subsequent emerging development of both monotherapy and co-administration with traditional cytotoxic medicines against solid tumors. Second-generation epigenetic agents such as EZH2 and BET inhibitors have greatly progressed. Epigenetic dysregulation has also provided feasibility for the diagnosis and treatment of cancer. In this review, we summarize the progress in epigenetics and drug discovery for cancer and certain clinical trials that may provide a perspective for future development.
Export Options
About this article
Cite this article as:
Jin Ping and Chen Xiaofei, Current Status of Epigenetics and Anticancer Drug Discovery, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (6) . https://dx.doi.org/10.2174/1871520616666151116124432
DOI https://dx.doi.org/10.2174/1871520616666151116124432 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Review on Pharmacological and Phytochemical Prospects of Traditional Medicinal Plant: <i>Persicaria hydropiper</i> (Smartweed)
Current Topics in Medicinal Chemistry Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry p42.3: An Abductor of Cell Cycle
Anti-Cancer Agents in Medicinal Chemistry Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design pH-Sensitive Polymer-Based Carriers as a Useful Approach for Oral Delivery of Therapeutic Protein: A Review
Protein & Peptide Letters Current Management of In Situ and Invasive Cervical Adenocarcinoma
Current Women`s Health Reviews It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII
Current Pharmaceutical Design Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Polyphenols and Aging
Current Aging Science Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagyetween Apoptosis and Autophagy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry